Quick Answer
Zomedica Corp. reported Operating Income Loss of -$84.35 million for the year ending 2025.
- Zomedica Corp. showed a decrease of -65.2% in Operating Income Loss from 2024 to 2025.
- This data is from Zomedica Corp.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$1.85 million | Q2 2017: -$1.59 million | Q3 2017: -$2.09 million | Q1 2018: -$2.17 million | Q2 2018: -$4.15 million | Q3 2018: -$1.85 million | Q1 2019: -$11.69 million | Q2 2019: -$2.39 million | Q3 2019: -$2.84 million | Q1 2020: -$2.33 million | Q2 2020: -$5.30 million | Q3 2020: -$5.00 million | Q1 2021: -$3.87 million | Q2 2021: -$5.33 million | Q3 2021: -$6.41 million | Q1 2022: -$4.31 million | Q2 2022: -$5.88 million | Q3 2022: -$6.59 million | Q1 2023: -$7.51 million | Q2 2023: -$6.74 million | Q3 2023: -$5.95 million | Q1 2024: -$10.39 million | Q2 2024: -$25.07 million | Q3 2024: -$7.44 million | Q1 2025: -$64.55 million | Q2 2025: -$8.04 million | Q3 2025: -$6.61 million.
- Over the full 10 years of available data (2016 to 2025), Zomedica Corp.'s Operating Income Loss has declined by 1,373.1%.
- Historical annual values: Fiscal year 2025: -$84.35 million | Fiscal year 2024: -$51.05 million | Fiscal year 2023: -$43.28 million | Fiscal year 2022: -$21.92 million | Fiscal year 2021: -$21.37 million | Fiscal year 2020: -$16.76 million | Fiscal year 2019: -$19.78 million | Fiscal year 2018: -$16.58 million | Fiscal year 2017: -$8.08 million | Fiscal year 2016: -$5.73 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: